9 years ago

Atlantic Healthcare Secures $24 Million for IBD Treatment Development

  • Atlantic Healthcare, a UK-based specialty pharma company focused on gastrointestinal disorders, has raised $24 million in equity financing

  • The funding will be used to conduct a Phase 3 trial for alicaforsen enema, their product to treat Inflammatory Bowel Disease (IBD) pouchitis, as well as to fund regulatory filings for approval with the U.S

  • FDA, EMA, and Health Canada

  • The round was led by the founders of Salix Pharmaceuticals, Fullbrook Thorpe Investments LLP, and LDC, the private equity division of Lloyds Banking Group plc, along with existing investors.

      • ProblemHealthcare

      "Millions of people suffer from inflammatory bowel disease (IBD) and the current treatments available aren't always effective or convenient."

      Solution

      "Atlantic Healthcare is developing alicaforsen enema, a new treatment for pouchitis and other inflammatory bowel diseases, which is delivered rectally and can be self-administered at home, making it more convenient for patients."

      Covered on